BREAKTHROUGH: Ciloa secures €6.5M from France 2030 to revolutionize diabetes and obesity treatment!

Ciloa has been awarded €6.5M through the France 2030 "Innovation in Biotherapies and Biomanufacturing" program to develop APN-sEV, the world's first stable and functional form of adiponectin. The funding will support GMP scalable manufacturing implementation and regulatory preclinical trials, with Phase I clinical trials planned for 2027 and Phase IIa in 2028.

France 2030 in action

The €54B France 2030 national investment plan is transforming key sectors through innovation - from fundamental research to industrialization. This is a perfect example of how strategic public investment accelerates breakthrough healthcare solutions!

What makes this Ciloa innovation revolutionary

• 20+ years of failed attempts worldwide to stabilize this "Guardian Angel" metabolism hormone
• Remarkable preclinical results against obesity and type 2 diabetes
• Preserves muscle mass (unlike current treatments)
• Potential to help 2 billion patients globally

Next steps funded by this program

• GMP manufacturing implementation
• 2027: Phase I clinical trials
• 2028: Phase IIa

Ciloa showcases how France 2030 and Bpifrance are positioning France as a leader in the world of tomorrow. 

Press release:  https://www.ciloa.bio/france-2030/